Molecular staging of prostate cancer: Dream or reality?

ONCOLOGY

Volumn 13, Issue 2, 1999, Pages 187-194

  De La Taille, Alexandre ^a   Olsson, Carl A ^a   Katz, Aaron E ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RNA;

CANCER STAGING; COMPARATIVE STUDY; GENETICS; HUMAN; MALE; METHODOLOGY; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR RECURRENCE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 0042878027     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:10-11, 1998.
2. Stephenson RA, Stanford JL: Population-based prostate cancer trends in the United States: Patterns of change in the area of prostate-specific antigen. World J Urol 15: 331-335, 1997.
3. Carter HB, Coffey DS: Prostate cancer: The magnitude of the problem in the United States, in Coffey DS, Resnick FA, Karr JP (eds): A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer, chap 1, pp 1-7. New York, Plenum Press, 1988.
4. Partin AW, Yoo J, Carter B, et al: The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostatic cancer. J Urol 150:110-114, 1993.
5. Rifkin MD, Zerhouni EA, Gatsonis CA, et al: Comparison of magnetic resonance imaging and ultrasound in staging early prostate cancer. N Engl J Med 323:621-626, 1990.
6. Partin AW, Carter HB, Chan DW, et al: Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747-752, 1990.
7. Katz AE, Olsson CA, Raffo AJ, et al: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43:765-775, 1994.
8. Katz AE, de Vries GM, Benson MC, et al: The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Urol Clin North Am 21:541-549, 1996.
9. Olsson CA, de Vries GM, Benson MC, et al: The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: Molecular staging of prostate cancer. Br J Urol 77: 411-417, 1996.
10. Olsson CA, de Vries GM, Raffo AJ, et al: Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 155:1557-1562, 1996.
11. Nejat RJ, Katz AE, Olsson CA: The role of reverse transcriptase-polymerase chain reaction for staging patients with clinically localized prostate cancer. Semin Urol Oncol 16:40-45, 1998.
12. Nejat RJ, Katz AE, Benson MC, et al: Enhanced RT-PCR for PSA combined with serum PSA predicts pathologic stage and outcome in 300 radical prostatectomy patients. J Urol 159:291A, 1998.
13. Grasso YZ, Gupta MK, Levin HS, et al: Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: Correlation with pathological stage. Cancer Res 58:1456-1459, 1998.
14. Wood DP, Banerjee M: Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 15:3451, 1997.
15. Israeli RS, Miller WH, Su SL, et al: Sensitive nested reverse transcriptase polymerase chain reaction detection of circulating prostate tumor cells: Comparison of prostate specific membrane antigen and prostate specific antigen based assays. Cancer Res 54:6306-6310, 1994.
16. Seiden MV, Kantoff PW, Krithivas K, et al: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 12:2634-2639, 1994.
17. Jaakkola S, Vornanen T, Leinonen J, et al: Detection of prostatic cells in peripheral blood: Correlation with serum concentrations of prostate specific antigen. Clin Chem 41:182-186, 1995.
18. Loric S, Dumas F, Eschwege P, et al: Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 41:1698-1704, 1995.
19. Sokoloff MH, Tso CL, Kaboo R, et al: Quantitative polymerase chain reaction does not improve preoperative cancer staging: A clinicopathological molecular analysis of 121 patients. J Urol 156:1560-1566, 1996.
20. Ghossein RA, Rosai J, Scher HI, et al: Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50: 100-105, 1997.
21. Kawakami M, Okaneya T, Furihata K, et al: Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2. Cancer Res 57:4167-4170, 1997.
22. Corey E, Arfman EW, Oswin MM, et al: Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 50:184-188, 1997.
23. Corey E, Arfman EW, Liu AY, et al: Improved protocol for reverse transcriptase polymerase chain reaction protocol with exogenous internal competitive control for prostate specific antigen mRNA in blood and bone marrow. Clin Chem 43:443-452, 1997.
24. Gomella LG, Raj GV, Moreno JG: Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 158:326-337, 1997.
25. Noguchi M, Miyajima J, Itoh K, et al: Detection of circulating tumor cells in patients with prostate cancer using prostate specific membrane-derived primers in the polymerase chain reaction. Int J Urol 4:374-379, 1997.
26. de Cremoux P, Ravery V, Podgorniak MP, et al: Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. Eur Urol 32:69-74, 1997.
27. Thiounn N, Saporta F, Flam TA, et al: Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology 50:245-250, 1997.
28. Ellis WJ, Vessella RL, Corey E, et al: The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and follow-up of patients with prostate cancer. J Urol 159:1134-1138, 1998.
29. Vessela RL, Lange PH, Blumenstein BA, et al: Multicenter RT-PCR PSA clinical trial for preoperative staging of prostate cancer. J Urol 159:292A, 1998.
30. Eschwege P, Dumas F, Blanchet P, et al: Cellules circulantes et cancer de prostate: Interêt en pratique quotidienne. Séminaires d'uro-néphrologie (France) 23:287, 1997.
31. Van Nguyen C, Song W, Scardino PT, et al: RT-PCR for PSA and hK2: Implications for staging and patient management in men undergoing radical prostatectomy. J Urol 159:292A, 1998.
32. Hedican SP, Nelson JB, Marshke P, et al: Evaluation of preoperative prostate cancer staging and postoperative detection of recurrence utilizing the reverse transcriptase polymerase chain reaction (RT-PCR). J Urol 159:292A, 1998.
33. Moreno JG, Croce CM, Fisher R, et al: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112, 1992.
34. Melchior SW, Corey E., Ellis WJ, et al: Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate (CAP). J Urol 155:554A, 1996.
35. Ignatoff JM, Oefelein MG, Watkin W, et al: Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. J Urol 158:1870-1875, 1997.
36. Slawin KM, O'Hara SM, Song W et al: Comparison of results obtained using different RT PCR PSA assay methods on a single set of clinical specimens. J Urol 155:417A, 1996.
37. Schellhammer PF: Radical prostatectomy: Patterns of local failure and survival in 67 patients. Urology 31:191-197, 1988.
38. Ohori M, Wheeler TM, Kattan MW, et al: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154:1818-1824, 1995.
39. Partin AW, Pound CR, Clemens JQ, et al: Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol Clin North Am 20:713-725, 1993.
40. Trapasso JG, de Kernion JB, Smith RB, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821-1825, 1994.
41. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152:1850-1857, 1994.
42. Pound CR, Partin AW, Epstein JI, et al: Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 24:395-406, 1997.
43. Humphrey PA, Frazier HA, Vollmer RT, et al: Stratification of pathologic features on radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. Cancer 71:1821-1827, 1993.
44. Epstein JI, Partin AW, Saugageot J, et al: Prediction of progression following radical prostatectomy: A multivariate analysis of 721 patients with long term follow-up. Am J Surg Pathol 20:286-292, 1996.
45. Paradis V, Echwege P, Loric S, et al: CD44 expression in prostate cancers is associated with blood dissemination. J Urol 159: 299A, 1998.
46. Eschwege P, Loric S, Paradis V, et al: Blood-borne prostate cells detection marks adhesion defect and recurrence in cancer. Eur Urol 33(suppl 1):36, 1998.